Algeta signs exclusive agreement with Lumiphore, Inc. to access proprietary technology to enhance its Thorium platform
Agreement aims to strengthen Algeta’s proprietary position around the development of novel tumor-targeted alpha-pharmaceuticals
27-Oct-2010 -
Algeta ASA announced it has entered into a technology access agreement with Lumiphore, Inc. that could enable Algeta to develop the next generation of cancer-targeting alpha-pharmaceuticals. The agreement provides Algeta with exclusive access to Lumiphore’s novel, patented Lumi4® chelator ...
antibodies
breast cancer
lymphoma
+4